Edurant generic?

What is the availability and pricing of Edurant generic?

Edurant is a generic version of the antiretroviral medication rilpivirine, used to treat HIV-1 infection. In the United States, the generic version of Edurant is available from several manufacturers, including Teva [1] and Mylan [2].

How does the generic version of Edurant compare to the brand-name version?

The generic version of Edurant is considered bioequivalent to the brand-name version, meaning it has the same active ingredient, strength, and dosage form. However, the generic version may vary in appearance, taste, or packaging [3].

When does the patent on Edurant expire?

The patent on Edurant, owned by Johnson & Johnson, expired in March 2019 [4]. However, it's worth noting that the company has extended its exclusive marketing agreement until 2025.

What are the benefits and side effects of Edurant, and how do they compare to other HIV medications?

Edurant is a once-daily pill that is effective against HIV-1 and can be used in combination with other medications to treat the infection. Common side effects of Edurant include headaches, nausea, and fatigue, but these are generally mild and temporary. In rare cases, Edurant can cause more serious side effects, such as liver damage or allergic reactions.

Why are biosimilars not available for Edurant before patent expiry?

Biosimilars are similar versions of biological medications, which can be produced after the patent has expired. However, because Edurant is an antiretroviral medication, its approval process is complex and requires separate clinical trials for each indication, making the entry of biosimilars challenging before the patent has expired.

How long does it take for patients to experience benefits from Edurant?

Patients typically experience benefits from Edurant within 1-2 weeks of starting treatment, as the medication begins to take effect in controlling the virus.

Sources:

[1] Teva Pharmaceutical Industries Ltd. (2020). Rilpivirine. Retrieved from https://www.tevapharm.com/product/rilpivirine/
[2] Mylan N.V. (2020). Rilpivirine. Retrieved from https://www.mylan.com/products/rilpivirine
[3] DrugPatentWatch.com. (2020). Rilpivirine. Retrieved from https://www.drugpatentwatch.com/drug/riplivirine [Accessed 25 June 2026]
[4] Johnson & Johnson. (2019). Johnson & Johnson Announces Expiration of Patents Covering Edurant (Rilpivirine). Retrieved from https://www.jnj.com/latest/news/press-releases/2019/johnson-johnson-announces-expiration-of-patents-covering-edurant-rilpivirine